Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

• Chen Wang,
• Kathy L. McGraw,
• Amy F. McLemore,
• Rami Komrokji,
• Ashley A. Basiorka,
• Najla Al Ali,
• Jeffrey E. Lancet,
• Eric Padron,
• Olivier Kosmider,
• Michaela Fontenay,
• Pierre Fenaux,
• Alan F. List,
• David A. Sallman

Affiliations

Chen Wang

Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Kathy L. McGraw

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Amy F. McLemore

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Rami Komrokji

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Ashley A. Basiorka

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Najla Al Ali

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Jeffrey E. Lancet

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Eric Padron

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Olivier Kosmider

Service d’Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris

Michaela Fontenay

Service d’Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris

Pierre Fenaux

Groupe Francophone des Myélodysplasies, Hopital Saint Louis, Paris

Alan F. List

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

David A. Sallman

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL